Journal of Clinical Medicine· 2026Q2
Indications for Biological Treatment Combined with Allergen-Specific Immunotherapy: Who Is It Really Intended for?
- 0citations
- Q2SCImago
- 2026year
Short summary
Combining biological agents like omalizumab and dupilumab with allergen-specific immunotherapy (AIT) shows promise for allergic asthma and food desensitization, particularly during high-risk dose escalation phases.
AI-generated from the title and abstract; the full text is not read.
Key points
- Biological agents (omalizumab, dupilumab) are being combined with allergen-specific immunotherapy (AIT) to improve outcomes for allergic conditions.
- Omalizumab plus AIT is effective for allergic asthma and during food desensitization, particularly for managing dose escalation risks.
- Clinical studies are investigating dupilumab's efficacy in various food allergies, including peanut and cow's milk protein, as monotherapy or adjunct to oral immunotherapy.
- Further research is needed to optimize dosing, duration, and patient selection for combined biological and AIT treatments.
AI-generated from the title and abstract; the full text is not read.
Abstract
Allergen-specific immunotherapy (AIT) is a well-proven treatment for allergic diseases and conditions such as Hymenoptera venom allergy, allergic rhinitis, allergic asthma, and, in recent years, food allergy. In order to enhance the efficacy and safety of allergen immunotherapy, biological agents such as omalizumab and dupilumab have been introduced. The use of omalizumab, in combination with AIT, has proven to be an effective option in treating patients with allergic asthma and during food desensitization, particularly in the dose escalation phase when adverse reactions are more common. To date, only a small number of well-structured clinical trials have been published on the combined use of biologics and AIT in patients with Hymenoptera venom allergy. Ongoing clinical studies are evaluating the efficacy of dupilumab as monotherapy or as an adjunct therapy to oral immunotherapy in patients with peanut allergy. Research is also underway on the use of dupilumab in patients with multiple food allergies and as an adjunct therapy to oral immunotherapy in patients with cow’s milk protein allergy. Further studies are needed to determine the optimal dosing and duration of biological therapy in combination with AIT, as well as to identify patients who may benefit most from such treatment regimes.
The authors' abstract, as published at the source. Journal of Clinical Medicine, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine